Market cap gains far exceed historical trends: In an equivalent time period prior to the launch of their GLP-1 products, the combined market cap gains for Novo Nordisk and Eli Lilly was significantly lower at $197 billion3.5x less than the gains realized after the introduction of these products
There is no approved pharmacy pathway, no approved prescription form, and no approved compounded formulation of retatrutide anywhere in the world
GLP-1 analogues are often prescribed for chronic conditions such as type 2 diabetes and obesity, which require ongoing, long-term management
Reduced appetite makes it easier to make better food choices without fighting constant hunger
If youre currently taking a compounded GLP-1, its a good time to talk with your healthcare provider about next steps
Access comprehensive market data, trends, and forecasts in one downloadable databook: Market Overview: Novel Use in Different Areas A class of drugs used in the management of type 2 diabetes and obesity is called GLP-1 receptor agonists
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
